Supplementary Material for: The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
datasetposted on 06.04.2021, 04:57 by Coleman R.L., Beck J.T., Baranda J.C., Jacobs I., Smoyer K.E., Lee L.J., Askerova Z., McGinnis J., Ganti A.K.
Objective: To investigate patient-reported outcome (PRO) usage in phase I oncology clinical trials, including types of PRO measures and changes over time. Methods: We analyzed ClinicalTrials.gov records of phase I oncology clinical trials completed by December 2019. Results: Of all eligible trials, 2.3% (129/5,515) reported ≥1 PRO, totaling 181 instances of PRO usage. PRO usage increased over time, from 0.6% (trials initiated before 2000) to 3.4% (trials starting between 2015 and 2019). The most common PRO measures were unspecified (29%), tumor-specific (24%), and generic cancer (19%). Conclusion: Although uncommon in phase I oncology clinical trials, PRO usage is increasing over time. PRO measures were often unspecified on ClinicalTrials.gov, suggesting that more precise reporting and standardization are needed.